NCT02592486 - The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

August 31, 2016

Conditions

Pneumococcal PneumoniaInfluenza

Interventions

BIOLOGICAL

Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®

Injections of pneumococcal vaccine and influenza vaccine simultaneously.

BIOLOGICAL

Sequential administration of Pneumovax NP® and Fluvic HA syringe®

Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.

Trial Locations (1)

Department of Pulmonary Medicine, Kameda Medical Center, Kamogawa